Better Access. Better Lives.
Who we are?
We specialize in making biosimilars - to improve lives by expanding access to affordable biologic medicines. We are purpose-driven and passionate about what we do.
We believe that a vertically integrated approach, from cell line development through fill and finish manufacturing, gives us the control, scale and speed needed to achieve our mission. We maintain our singular focus on what we do best while relying on the deep expertise of our partners for commercialization.
We are committed to developing and manufacturing high-quality, cost-competitive biosimilars. We continually evaluate additional pipeline opportunities to bring a strategic and robust selection of biologic medicines to patients around the world.
Alvotech to Report First Six Months and Second Quarter 2022 Financial Results on August 31, 2022 and Host Business Update Conference Call at 8:00 am ET on September 1, 2022
Alvotech’s Board of Directors Approves Plan to Prepare for Listing on Nasdaq Main Market in Iceland
Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
Join our team
Here at Alvotech, we want our employees to feel inspired in their careers and challenged by interesting and meaningful work. That’s why we are proud of our purpose-driven culture. We are always interested in speaking to passionate, experienced individuals. Are you ready to join our growing team?